Mostrar el registro sencillo del ítem
dc.contributor.author | Aldámiz-Echevarria, Teresa | |
dc.contributor.author | Resino, Salvador | |
dc.contributor.author | Bellón, José M | |
dc.contributor.author | Jimenez-Sousa, Maria Angeles | |
dc.contributor.author | Miralles, Pilar | |
dc.contributor.author | Medrano, Luz Maria | |
dc.contributor.author | Carrero, Ana | |
dc.contributor.author | Díez, Cristina | |
dc.contributor.author | Pérez-Latorre, Leire | |
dc.contributor.author | Fanciulli, Chiara | |
dc.contributor.author | Garcia-Broncano, Pilar | |
dc.contributor.author | Berenguer, Juan | |
dc.date.accessioned | 2019-11-04T09:47:55Z | |
dc.date.available | 2019-11-04T09:47:55Z | |
dc.date.issued | 2019-07-26 | |
dc.identifier.citation | J Transl Med. 2019 Jul 26;17(1):244 | es_ES |
dc.identifier.issn | 1479-5876 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/8546 | |
dc.description.abstract | BACKGROUND: Mitochondrial DNA (mtDNA) haplogroups have been associated with advanced liver fibrosis and cirrhosis in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Our aim was to determine whether mtDNA haplogroups are associated with liver-related events (LREs) in HIV/HCV-coinfected patients. METHODS: We carried out a retrospective cohort study in HIV/HCV-coinfected patients who were potential candidates for therapy with interferon and ribavirin (IFN/Rib) between 2000 and 2009. The primary endpoint was the occurrence of LREs (decompensation or hepatocellular carcinoma). mtDNA genotyping was performed using the Sequenom MassARRAY platform. We used Fine and Gray proportional hazards model to test the association between mtDNA haplogroups and LREs, considering death as a competitive risk. RESULTS: The study population comprised 243 patients, of whom 40 had advanced fibrosis or cirrhosis. After a median follow-up of 7.7 years, 90 patients treated with IFN/Rib achieved sustained viral response (SVR), 18 patients had LREs, and 11 patients died. Patients with haplogroup H had lower cumulative incidence than patients with other haplogroups (p = 0.012). However, patients with haplogroup T had higher cumulative incidence than patients with other haplogroups (p = 0.074). In the multivariate analysis, haplogroup T was associated with an increased hazard of developing LREs [adjusted subhazard ratio (aSHR) = 3.56 (95% CI 1.13;11.30); p = 0.030]; whereas haplogroup H was not associated with lower hazard of LREs [aSHR = 0.36 (95% CI 0.10;1.25); p = 0.105]. When we excluded patients who achieved SVR during follow-up, we obtained similar SHR values. CONCLUSIONS: European mitochondrial haplogroups may influence the natural history of chronic hepatitis C. | es_ES |
dc.description.sponsorship | This study was supported by grants from Fondo de Investigación de Sanidad en España (Spanish Funds for Health Research [FIS]), grant numbers PI14/01094 and PI17/00657 to JB, PI14CIII/00011 and PI17CIII/00003 to SR. The study was also funded by the RD16CIII/0002/0002 and RD16/0025/0017 projects as part of the Plan Nacional R + D + I and cofunded by ISCIII- Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Refs INT15/00079 and INT16/00100. LMM, MAJS, and PGB are supported by “Instituto de Salud Carlos III” (grant numbers CD14/00002, CD13/00013, CP14/0010, and FI12/00036; respectively). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BioMed Central (BMC) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Chronic hepatitis C | es_ES |
dc.subject | Cirrhosis | es_ES |
dc.subject | HIV | es_ES |
dc.subject | Liver-related outcomes | es_ES |
dc.subject | Mitochondria | es_ES |
dc.subject | mtDNA haplogroups | es_ES |
dc.title | European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 31349790 | es_ES |
dc.format.volume | 17 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | 244 | es_ES |
dc.identifier.doi | 10.1186/s12967-019-1997-x | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1479-5876 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1186/s12967-019-1997-x | es_ES |
dc.identifier.journal | Journal of translational medicine | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI14/01094 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI17/00657 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI14CIII/00011 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI17CIII/00003 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RD16CIII/0002/0002 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RD16/0025/0017 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/INT15/00079 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/INT16/00100 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/CD14/00002 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/CD13/00013 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/CP14/0010 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/FI12/00036 | es_ES |
dc.rights.accessRights | open access | es_ES |